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Abstract
Background KN motif and ankyrin repeat domains 1 (KANK1) plays an important role in cytoskeleton maintenance and 
contributes to the regulation of cell proliferation, adhesion and apoptosis. KANK1 is involved in progression of a variety of 
solid tumours; however, its role in invasive breast cancer (BC) remains unknown. This study aims to evaluate the clinico-
pathological and prognostic value of KANK1 expression in operable BC.
Methods KANK1 expression was assessed at the transcriptomic level using multiple BC cohorts; the Molecular Taxonomy 
of BC International Consortium cohort (METABRIC; n = 1980), The Cancer Genome Atlas BC cohort (TCGA; n = 949) and 
the publicly available BC transcriptomic data hosted by BC Gene-Expression Miner (bc-GenExMiner v4.0) and Kaplan–
Meier plotter?. The Nottingham BC cohort (n = 1500) prepared as tissue microarrays was used to assess KANK1 protein 
expression using immunohistochemistry (IHC). The association between clinicopathological variables and patient outcome 
was investigated.
Results In the METABRIC cohort, high expression of KANK1 mRNA was associated with characteristics of good prognosis 
including lower grade, absence of lymphovascular invasion and HER2 negativity (all; p < 0.001) and with better outcome 
[p = 0.006, Hazards ratio, (HR) 0.70, 95% CI 0.54–0.91]. High KANK1 protein expression was correlated with smaller 
tumour size and HER2 negativity, and better outcome in terms of longer breast cancer-specific survival [p = 0.013, HR 0.7, 
95% CI 0.536–0.893] and time to distant metastasis [p = 0.033, HR 0.65, 95% CI 0.51–0.819].
Conclusion These results supported that upregulation of KANK1 works as a tumour suppressor gene in BC and is associ-
ated with improved patients’ outcomes.
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Background
Breast cancer (BC) is a heterogeneous disease associated 
with a variety of morphological, molecular features, out-
comes and response to therapy [1]. Although BC outcome Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s1054 9-019-05466 -8) contains 
supplementary material, which is available to authorized users.
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has improved over the years, 20–30% of patients develop 
distant metastasis with subsequent poor outcome [2]. Several 
mechanisms are involved in BC metastasis; however, the key 
molecular factors driving metastasis remain to be defined.
KN motif and ankyrin repeat domains 1 gene (KANK1) is 
located at chromosome 9p24 [3] and is composed of KANK 
N-terminal (KN) motif, the central coiled-coil domains and 
the C-terminal ankyrin (ANK) repeats [4]. Notably, KANK1 
protein interacts with other associated proteins via the 
coiled-coil and the ankyrin repeat domains, respectively [4]. 
KANK1 has an essential role in cytoskeleton maintenance 
via regulating the rate of cytoskeleton proteins production 
and controlling actin polymerisation [4]. KANK1 plays an 
important role in the down-regulation of the Rho-associ-
ated kinase (ROCK) pathway [5], which is recognised to 
be involved in various cellular functions such as prolifera-
tion, adhesion, cell differentiations and apoptosis [6]. This 
allow KANK1 to integrate alongside with β-catenin aiming 
to regulate its distribution in the nucleus and concentrate its 
transcription, therefore, affecting the development of can-
cer [7]. Importantly, several in vivo studies revealed a link 
between the ROCK pathway and tumour cell metastasis [8, 
9] and indicated its role in multiple human cancers includ-
ing BC [6].
The signalling processes controlled by KANK1 expres-
sion are also involved in the regulation of epithelial mes-
enchymal transmission (EMT) by cooperating with trans-
forming growth factor-β (TGF-β) to induce the cytoskeletal 
reorganisation [10]. KANK1 plays an important role in the 
development of many malignant tumours. For instance, 
in vivo KANK1 overexpression reduces the tumorigenic-
ity in lung cancer [11]. Further, in vivo and in vitro studies 
confirm that KANK1 upregulation in gastric cancer leads 
to a decrease in the metastatic ability of tumour cells [12]. 
However, the prognostic significance of KANK1 expres-
sion in BC remains unclear. This study aimed to assess 
the biological and clinical significance of KANK1 mRNA 
and KANK1 protein expression in BC and the association 
between KANK1 mRNA expressions with EMT-related 
genes.
Materials and methods
Study cohorts
KANK1 transcriptomic data
The molecular taxonomy of breast cancer international con-
sortium (METABRIC) dataset (n = 1980) [13] was used to 
evaluate KANK1 mRNA expression. In the METABRIC, 
mRNA extracted from primary tumour samples was assayed 
using the Illumina Human HT-12 v3 platforms (Illumina, 
Inc., San Diego, USA). Gene-expression data were prepared 
and normalised as described previously [14]. Furthermore, 
The Cancer Genome Atlas (TCGA) BC dataset (n = 895) 
[15] was used to evaluate KANK1 mRNA expression. In the 
TCGA cohort, RNASeqV2 data and clinicopathological 
information provided by cBioPortal were used [16, 17]. The 
prognostic value of KANK1 mRNA expression was further 
evaluated using the online Breast Cancer Gene-Expression 
Miner v4.0 (bc-GenExMiner v4.0) database (n = 3871) [18] 
and the Kaplan–Meier plotter (n = 1402) [19].
KANK1 protein expression
KANK1 protein cohort
A well-characterised cohort of primary operable BC was 
incorporated in this study, in which the cases were collected 
from patients presented to Nottingham City Hospital, NHS 
Trust between 1998 and 2006 (Supplementary Table 1). The 
Nottingham Prognostic Index (NPI) and oestrogen receptor 
(ER) status were used to classify patients into clinically rel-
evant groups for management purposes. Based on the NPI, 
patients were sub-classified into two groups; patients with 
NPI > 3.4 received tamoxifen if ER status was positive and 
chemotherapy if ER was negative; however, patients who 
had NPI ≤ 3.4 received no adjuvant therapy. Patients lacking 
ER expression (ER) and eligible to receive chemotherapy 
were treated with classical cyclophosphamide, methotrex-
ate and 5-flurouacil (CMF). Neoadjuvant therapy or anti-
Her2-targeted therapy was not used to treat patients in this 
study. Information of therapy, clinical history and outcomes 
are prospectively maintained. Outcome data included devel-
opment and time to distant metastasis (TTDM) and breast 
cancer-specific survival (BCSS) [20]. BCSS was defined as 
the duration (in months) from the date of primary surgery 
to the time of death because of BC. Distant metastasis-free 
interval was defined as the duration (in months) from pri-
mary surgical treatment to the occurrence of first distant 
recurrence. The distribution of clinicopathological param-
eters between the discovery cohort (METABRIC) and the 
validation cohort (Nottingham) presented no statistical dif-
ferences (all correlation coefficients (r) = 0.80, all p < 0.001).
Immunohistochemistry (IHC)
KANK1 antibody (rabbit polyclonal SAB500862; SIGMA 
Company, USA) specificity was assessed by western blot 
using human BC cell lysates from MCF7 and SKBR3 
(obtained from the American Type culture Collection; 
Rockville, MD, USA). KANK1 antibody (1:500 dilution) 
was incubated overnight and showed a single band at the 
expected molecular weight – 90 kDa and mouse β-actin 
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(A5441, Sigma-Aldrich; Clone AC-15; Sigma, UK) at 
1:5000 was used as a house-keeping protein (Fig. 1a).
To evaluate the pattern and distribution of KANK1 pro-
tein expression, full-face tissue sections (n = 14), representa-
tive of different BC molecular subtypes and tumour grades, 
were stained. Tumour samples were arrayed onto TMAs as 
previously described using the TMA Grand Master® (3D 
HISTECH®, Budapest, Hungary) [21]. The Novolink Max 
Polymer Detection system (Leica, Newcastle, UK) was used 
to detect the immunoreactivity of KANK1. Heat-induced 
retrieval of antigen epitopes was performed in citrate solu-
tion (pH 6.0). KANK1 antibody was incubated at room tem-
perature for 1 h (dilution 1:1500).
Scoring of KANK1 protein expression
The stained slides were scanned into high-resolution digital 
images at ×20 magnification using a Nanozoomer scanner 
(Hamamatsu Photonics, Welwyn Garden City, UK). KANK1 
cytoplasmic immunoreactivity was evaluated using the 
modified H-score taking the staining intensity and percent-
age of positivity into account. Staining intensity (0–3) was 
multiplied by the proportion of tumour cells (0–100) stained 
with each intensity and final scores were obtained, giving a 
range of 0–300 [22]. Double scoring was assessed blindly by 
two researchers to evaluate the inter-observer concordance. 
Intraclass correlation coefficient (ICC) concordance between 
both observers was 0.9.
Statistical analysis
SPSS (IBM SPSS Statistic, Version 24.0) was used in sta-
tistical analysis. Pearson correlation test was used to evalu-
ate the relationship of KANK1 mRNA expression with the 
expression of a set of genes known to be associated with 
EMT and cancer cell migration (CDH1, CDH2, TGFB, 
TWIST2, TWIST1, ZEB2, ZEB1 SLUG, SNAIL, NFKB1, 
LLGL2, GSK3B, CRUMBS and CTNNB1). The correla-
tion between KANK1 expression and clinicopathological 
factors was analysed using Chi-square test. Kaplan–Meier 
survival curves using the log-rank test were used to 
assess the prognostic significance of KANK1 expres-
sion. Cox proportional hazard method was employed for 
the multivariate survival analysis. KANK1 mRNA/pro-
tein expression did not follow a normal distribution and 
was dichotomised using median cut-off values (95). The 
p value < 0.05 (two-tailed) was considered statistically 
significant for clinicopathological parameters and sur-
vival. This work was preformed according to REMARK 
guidelines or tumour prognostic study [23], and approved 
ethically approval by the North West–Greater Manchester 
Central Research Ethics Committee under the title: Not-
tingham Health Science Biobank (NHSB), reference num-
ber 15/NW/0685.
Fig. 1  Western blot and immunohistochemical expression of KANK1 
in BC. a Western blotting results for KANK1 expression in MCF7 
and SKBR3 breast cancer cell lines using rabbit polyclonal antibody 
against human KANK1 (details). Green bands represent KANK1. 
Morphological characteristics of KANK1 immunohistochemis-
try in full-face breast cancer tissue. b–d Normal mammary gland 
cells showed uniformly strong KANK1 staining. b The reactivity of 
myoepithelial cells (c) was lower than those of epithelial cells (white 
arrow: normal epithelial cells). Invasive cancer cells (d) showed uni-
formly weak KANK1 staining. The reactivity was mainly observed 
in the cytoplasm. KANK1 protein expression in breast cancer TMA 
cores (e, f). Showing weak staining (e, f) strong staining in the cyto-
plasm of cancer cells
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Results
Clinicopathological significance of KANK1 mRNA 
expression
High KANK1 mRNA expression was significantly indicative 
of good prognosis as cases with high KANK1 mRNA expres-
sion had better BCSS outcome compared to low KANK1 
mRNA expression (p = 0.036; Fig. 2a). Similar associations 
were observed in the bc-GenExMiner v4.0 and KM plot-
ter BC datasets (Supplementary Fig. 1a, b). High KANK1 
mRNA expression was also associated with improved out-
come when restricting the analysis to subgroups including 
ER negativity (METABRIC: p = 0.007; TCGA: p < 0.001), 
HER2 negativity (METABRIC: p < 0.001; TCGA: 
p < 0.001) and LVI negativity (METABRIC: p = 0.005; 
TCGA: p = 0.003; Table 1). 
KANK1 mRNA overexpression was associated with 
higher expression of CDH1 (METABRIC: p = 0.022; 
TCGA: p < 0.001), CTNNB1 (METABRIC: p < 0.001; 
TCGA: p < 0.001); however, KANK1 mRNA overexpression 
was correlated with lower LLGL2 (METABRIC: p = 0.002; 
TCGA: p < 0.001) (Table 2).
KANK1 protein expression
BC full-face sections showed homogenous cytoplasmic 
expression of KANK1. KANK1 expression in normal glan-
dular epithelium was uniformly strong (Fig. 1b). KANK1 
immunoreactivity of myoepithelial cells was lower than 
those of glandular epithelial cells (Fig. 1c). In contrast, inva-
sive cancer cells exhibited weaker expression of KANK1 
compared to the normal mammary epithelial cells present 
in some TMA cores (Fig. 1d).
Using the median H-score (95) as a cut-off point, high 
KANK1 expression was observed in 599/1500 (40%) of 
tumours (Fig. 1e, f). High KANK1 protein expression was 
associated with smaller tumour size (p = 0.012) and HER2 
positivity (p = 0.007; Table 3).
Those patients with tumours showing high KANK1 
protein expression had significantly better 10 years BCSS 
(p = 0.024; Fig. 2b) and longer TTDM (p = 0.048; Fig. 2c) 
compared with those patients showing low/reduced KANK1 
expression. Multivariate analyses indicated that high 
KANK1 expression is correlated (< 0.05) with better out-
come in terms of longer BCSS and TTDM, independent of 
other established prognostic variables including tumour size, 
Nottingham grade, nodal stage, LVI, ER status, PR status 
and HER2 status (Table 4). 
When we stratified our BC cohort based on hormonal 
receptor and HER2 expression, overexpression of KANK1 
protein was predictive of longer BCSS in the receptor-nega-
tive subgroups (p = 0.024, p = 0.038 and p = 0.014 for ER−, 
PR− and HER2− tumours, respectively; Fig. 3a–c). TTDM 
showed similar association in both ER and HER2-negative 
BC (p = 0.027 and p = 0.014) (Fig. 3d, e). Importantly, when 
exploring the value of KANK1 protein expression in TNBC 
(n = 203), high KANK1 expression was also associated with 
prolonged survival (BCSS: p = 0.036 and TTDM p = 0.025; 
Fig. 4).  
Discussion
This study has robustly demonstrated that high KANK1 
expression is associated with good prognostic characteristics 
and improved BC patients’ outcomes, which is in agreement 
with other cancers including gastric [11], nerve [24] and 
lung [25]. Our study also showed that high KANK1 mRNA 
Fig. 2  KANK1 patient overall survival and time to distant metasta-
sis. a METABRIC cohort, BC overall survival was significantly bet-
ter in high KANK1 mRNA expression group than in the low KANK1 
expression group. b KANK1 protein expression BC overall survival 
was significantly better in the high KANK1 protein expression group 
than in the low expression group. c KANK1 protein expression BC 
TTDM was significantly better in the high KANK1 protein expres-
sion group than the low expression group
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expression showed improved survival time in the aggressive 
and clinically relevant subgroups of BC, namely ER, PR and 
HER2-negative tumours. It was also strongly associated with 
clinicopathological variables characteristic of good progno-
sis including LVI negativity and lower grade, highlighting a 
potential tumour suppressive role in BC.
In the current study, high KANK1 mRNA expression was 
associated with ER, PR and HER2 negativity. This is consist-
ent with KANK1 protein, except for HER2. This discrepancy 
in KANK1:HER2 expression between the protein and tran-
script levels may be attributable to the nature of the cohort, 
complicated post-transcriptional mechanisms and proteins 
may differ substantially in their in vivo half-lives [24, 25]. 
However, due to the relatively small sample size of the HER2-
positive subgroup, further confirmation in larger cohorts of 
both HER2-positive and HER2-negative cases is required to 
determine the exact role of KANK1 in HER2-positive BC.
Nonetheless, when investigating the role of KANK1 
mRNA expression with well-established EMT tran-
scription factors, our data showed a negative correlation 
between KANK1 mRNA expression and other EMT genes 
(TGFB1, CDH2, LLGL2 and CTNNB1). On the other hand, 
high KANK1 mRNA expression showed a significant posi-
tive association with E-cadherin gene (CDH1), and these 
Table 1  Association of 
KANK1 mRNA expression 
with clinicopathological 
characteristics in the 
METABRIC (n = 1980) and 
TCGA (n = 895) datasets
METABRIC the molecular taxonomy of breast cancer international consortium, TCGA the cancer genome 
atlas
Parameters METABRIC cohort TCGA cohort
Low KANK1 High KANK1 p value Low KANK1 High KANK1 p value
N (%) N (%) N (%) N (%)
Tumour size
 ≤ 2.0 cm 407 (47) 452 (53) 0.033 112 (47) 127 (53) 0.29
 >2.0 cm 575 (52) 526 (48) 315 (51) 300 (49)
Nodal stage
 Negative 502 (49) 533 (519) 0.14 193 (45) 233 (55) 0.007
 Positive 487 (52) 451 (48) 231 (55) 192 (45)
Lymphovascular invasion
 Negative 437 (47) 493 (53) 0.005 258 (46) 301 (54) 0.002
 Positive 344 (54) 291 (45) 169 (57) 126 (43)
Histological grade
 Grade 1 and 2 433 (46) 507 (54) 0.001 229 (49) 235 (51) 0.62
 Grade 3 513 (54) 439 (46) 180 (51) 172 (49)
Oestrogen receptor
 Negative 211 (44) 263 (56) 0.007 66 (35) 119 (65) < 0.001
 Positive 779 (52) 727 (48) 345 (54) 294 (46)
Progesterone receptor
 Negative 482 (51) 458 (49) 0.3 119 (44) 153 (56) 0.018
 Positive 508 (49) 532 (51) 288 (53) 258 (47)
Human epidermal growth factor receptor 2
 Negative 817 (47) 916 (53) < 0.001 254 (45) 313 (55) <  0.001
 Positive 173 (70) 74 (30) 94 (71) 39 (29)
Table 2  Correlation of KANK1 mRNA expression with mRNA 
expression of EMT-related genes
METABRIC the molecular taxonomy of breast cancer international 
consortium, TCGA the cancer genome atlas
Gene names METABRIC cohort TCGA cohort
Correlation 
value
p value Correlation 
value
p value
CDH1 0.052 0.022 0.147 < 0.001
CDH2 − 0.074 0.001 − 0.035 0.31
TGFB1 − 0.043 0.054 − 0.157 < 0.001
TWIST2 0.146 < 0.001 − 0.004 0.9
TWIST1 0.024 0.29 − 0.44 0.2
ZEB2 0.146 < 0.001 0.061 0.075
ZEB1 0.008 0.73 0.016 0.65
SLUG 0.193 < 0.001 0.143 < 0.001
SNAIL 0.014 0.54 0.061 0.075
NFKB1 0.069 0.002 0.057 0.095
LLGL2 − 0.237 0.002 − 0.118 < 0.001
GSK3B − 0.193 < 0.001 0.094 0.006
CRUMBS − 0.092 < 0.001 61 0.075
CTNNB1 0.206 < 0.001 0.222 < 0.001
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findings suggest that high KANK1 expression is involved 
in reducing tumour cell migration and influencing the LVI 
process through reducing the RhoA/ROCK pathway, which 
has a well-known role in controlling cancer cell migration 
[7]. TGFB1 acts as an oncogene in tumour progression 
by inducing cell invasion, dissemination to distant sites 
and augmenting angiogenesis. CDH2 and LLGL2, which 
play an important role in EMT activation, were negatively 
correlated with KANK1 high expression. This suggested 
that the EMT activation is prohibited by the presence of 
TGFB1, CDH2 and LLGL2. Chen et al. showed in gastric 
cancer, increased KANK1 expression was associated with 
smaller tumour size; results in agreement with our study 
results in both mRNA and protein levels, implying its role 
in decreasing cellular proliferation. Similarly, KANK1 
may regulate the cell proliferation through inhibiting the 
phosphorylation of PI3 K/AKT proteins [26]. Smaller 
tumour size and negative association with TGFB1, CDH2 
and LLGL2 strengthen the tumour suppressive role of 
KANK1.
In the whole BC cohort, high KANK1 protein expression 
was an independent prognostic marker for improved patients’ 
outcomes in terms of both BCSS and TTDM. Among sub-
groups, high expression of KANK1 protein appears to play 
the most significant survival role in TNBC. As TNBCs are 
highly resistance to chemotherapy compared to other BC 
types and strongly associated with worse clinical outcome, 
our results may indicate the promising role of KANK1 in 
this aggressive subtype regarding benefit from neoadjuvant 
chemotherapy and improved overall survival [27].
Our results suggest that loss of expression of KANK1 
promotes BC progression. This is in concordance with pre-
vious reports indicating that reduced expression of KANK1 
facilitates metastasis in different types of cancer and further 
reinforces its role as a prognostic indicator [11, 24, 25].
In summary, high KANK1 expression in BC is associ-
ated with favourable prognostic parameters and is an inde-
pendent prognostic factor with prolonged patient survival. 
KANK1 appears to play a role in inhibiting tumour cells 
proliferation, migration, invasion and metastasis. Further 
functional studies to decipher the role of KANK1 and its 
Table 3  Statistical association between KANK1 protein expression 
and clinicopathological characteristics of the studies cohort
Parameters KANK1 protein expression
Low High p value
N (%) N (%)
Tumour size
 ≤ 2.0 cm 382 (47.9) 415 (52.1) 0.012
 > 2.0 cm 290 (55.0) 237 (45.0)
Nodal stage
 Negative 408 (50.0) 408 (50.0) 0.46
 Positive 263 (52.1) 242 (47.9)
Lymphovascular invasion
 Negative 461 (49.5) 471 (50.5) 0.15
 Positive 211 (53.8) 181 (46.2)
Histological grade
 Grade 1 and 2 360 (51.6) 337 (48.4) 0.49
 Grade 3 312 (49.8) 315 (50.2)
Nottingham Prognostic Index
 Good prognostic group 198 (47.4) 220 (52.6) 0.22
 Moderate prognostic group 361 (52.8) 323 (47.2)
 Poor prognostic group 112 (51.4) 106 (48.6)
Oestrogen receptor
 Negative 133 (47.3) 148 (52.7) 0.2
 Positive 540 (51.7) 505 (48.3)
Progesterone receptor
 Negative 276 (49.6) 281 (50.4) 0.47
 Positive 393 (51.6) 369 (48.4)
Human epidermal growth factor receptor 2
 Negative 599 (52.6) 539 (47.4) 0.00074
 Positive 74 (39.4) 114 (60.6)
Triple negative breast cancer
 Negative 571 (51) 549 (49)
 Positive 102 (49) 104 (51) 0.699
Table 4  Multivariate Cox 
proportional hazard regression 
analysis for predictors of BCSS 
and time to distant metastasis 
(TTDM) in the Nottingham BC 
cohort
Factors BCSS TDDM
Hazard 
Ratio
95% CI p value  
(< 0.05)
Hazard 
ratio
95% CI p value  
(< 0.05)
KANK1 expression 1.4 1.072–1.786 0.0013 1.3 1.02–1.64 0.033
Tumour size 0.78 0.59–1.02 0.065 0.68 0.53–0.88 0.003
Tumour grade 1.62 1.26–2.08 < 0.0001 1.35 1.08–1.68 0.008
Tumour stage 1.78 1.50–2.13 < 0.0001 1.65 1.40–2.00 < 0.0001
Lymophvascular 
invasion
0.54 0.41–0.71 < 0.0001 0.55 0.43–0.88 < 0.0001
ER status 1.11 0.79–1.57 0.544 0.99 0.71–1.38 0.95
PR status 0.57 0.42–0.78 < 0.0001 0.68 0.50–0.88 0.004
HER2 expression 0.76 0.56–1.04 0.09 0.67 0.50–0.90 0.007
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mechanism of action as a tumour suppressive driver of 
invasive BC is warranted.
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